Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft

Abhik Bandyopadhyay, Fernando López-Casillas, Shazli N. Malik, José Luis Montiel, Valentín Mendoza, Junhua Yang, L. Z. Sun

Research output: Contribution to journalArticlepeer-review

114 Scopus citations


We have demonstrated previously that ectopic expression of a soluble betaglycan, also known as transforming growth factor (TGF) β type III receptor, can suppress the malignant properties of human carcinoma cells by antagonizing the tumor-promoting activity of TGF-β (A. Bandyopadhyay et al., Cancer Res., 59: 5041-5046, 1999). In the current study, we investigated the potential therapeutic utility of a recombinant preparation of human and rat soluble betaglycan (sBG). Purified recombinant human sBG showed similar properties to its rat counterpart (M. M. Vilchis-Landeros et al., Biochem J., 355: 215-222, 2001). It bound TGF-β with high affinity and isoform selectivity and neutralized the activity of TGF-β1 in two bioassays. Peritumoral (50 μg/tumor, twice a week) or i.p. (100 μg/animal, every alternate day) injection of sBG into human breast carcinoma MDA-MB-231 xenograft-bearing athymic nude mice significantly inhibited the tumor growth. The administration of sBG also reduced metastatic incidence and colonies in the lungs. The tumor-inhibitory activity of sBG was found to be associated with the inhibition of angiogenesis. Systemic sBG treatment significantly reduced tumor microvessel density detected with histological analyses and CD-31 immunostainings, as well as tumor blood volume measured with hemoglobin content. In an in vitro angiogenesis assay, treatment with the recombinant sBG significantly reduced the ability of human dermal microvascular endothelial cells to form a capillary tube-like structure on Matrigel. These findings support the conclusion that sBG treatment suppresses tumor growth and metastasis, at least in part by inhibiting angiogenesis. As such, it could be a useful therapeutic agent to antagonize the tumor-promoting activity of TGF-β.

Original languageEnglish (US)
Pages (from-to)4690-4695
Number of pages6
JournalCancer Research
Issue number16
StatePublished - Aug 15 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft'. Together they form a unique fingerprint.

Cite this